Compare AST SpaceMobile Inc (ASTS) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs BioNano Genomics Inc — how do they compare? AST SpaceMobile Inc trades at $74.43 (market cap $20.54B), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: AST SpaceMobile Inc is far larger — about 1503.7× BioNano Genomics Inc's market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | BNGO | |
|---|---|---|
Market Cap | $20.54B | $13.66M |
Sector | Media | Health |
52-Week High | $133.09 | $4.92 |
52-Week Low | $36.91 | $1.06 |
Enterprise Value | $21.25B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASTS trades at $68.76, down 4.42% today, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 revenue of $31.5 million, missing estimates, but reaffirmed full-year guidance of $150-200 million. Financials show significant losses, with a net income margin of -573.67% in 2026, though revenue growth is accelerating. Analyst consensus is mixed with a $84.63 price target, and recent news highlights partnerships with SpaceX and expansion in Europe.
The outlook is speculative with high growth potential from satellite network deployment, but substantial cash burn and execution risks persist. Investment opportunity lies in the $1.3 billion backlog and commercial service rollout, while risks include continued losses, high valuation multiples, and competitive pressures in the space sector.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
